GlassScriptPhysician profile
Stephen J Kolb
NPI 1477608388
$40,778.67
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $13K · 2021: $5,290 · 2022: $219 · 2023: $174 · 2024: $641.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $641 · Food and Beverage: $174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $641.00 |
| Food and Beverage | $173.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Gene Therapies, INC. (Fka Avexis, INC.) | $18,383.88 | 2019-2020 | |
| Biogen, INC. | $8,340.22 | 2019-2023 | Spinraza |
| Genentech, INC. | $5,906.12 | 2019 | |
| Genentech USA, INC. | $5,248.00 | 2020-2021 | |
| F. Hoffmann-La Roche Ag | $2,040.00 | 2021 | |
| Regeneron Pharmaceuticals, INC. | $641.00 | 2024 | |
| Alnylam Pharmaceuticals INC. | $219.45 | 2022 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Kolb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.